Williams P D, Callanan D, Solley W, Avery R L, Pieramici D J, Aabert T., Clin Ophthalmol.A Randomized, Dose-escalation Study of Subconjunctival and Intravitreal Injections of Sirolimus in Patients with Diabetic Macular Dugel P U, Blumenkranz M S, Haller J A, Williams G A, Solley W A, Kleinman D M, Naor J,: Ophthalmology.Sub-Investigator: AGN 150998: Single-Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-Related Macular Degeneration.Sub-Investigator: LUX 211-11: A Double-Masked, Placebo Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Non-Infectious Intermediate, Posterior or Pan-Uveitis.Sub-Investigator: AGN 206207-024: A Multi-Center, Open-Label, Randomized Study comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in patients with Diabetic Macular Edema.Sub-Investigator: iDeal 2010-007-03: A Randomized, Multi-Center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injection(s) iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the Foveal Center.Sub-Investigator: TRA-OZAB-11-001: The Effect of Ozurdex (Dexamethasone Intravitreal Implant) 0.7mg on Efficacy of Bevacizumab Therapy for Non-Ischemic Retinal Vein Occlusion.Sub-Investigator: Regeneron VGFTe-AMD-1124: An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.Sub-Investigator: Alcon: LHA510-2201: A Randomized, Double-Masked, Vehicle-Controlled, Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients with Wet, Age-Related Macular Degeneration.Sub-Investigator: ACT 13480: (SANOFI): A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Effixacy and Safety of Sarilumab Administered Subcutaneously Every Two Weeks in Patients with Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU).Sub-Investigator: AGN 150998-003: A Multi-Center, Double-Masked, Randomized, 20-Week Parallel-Group, Active Controlled Study, Designed to Evaluate the Safety and Treatment Effects of Abicipar in Treatment-Naïve Patients with Neovascular AMD.Sub-Investigator: AGN 150998-004: A Multi-Center, Randomized, Double-Masked, 28-week, Parallel-Group, Active-Controlled, to Evaluate the Safety and Treatment Effects of Abicipar in Patients with Decreased Vision Due to DME Involving the Central Foveal Subfield.

Texas retina associates fort worth jobs